The role of osteopontin in tumorigenesis and metastasis

Invasion and Metastasis

Volumn 17, Issue 1, 1997, Pages 1-15

  Oates, Adam J ^a   Barraclough, Roger ^b   Rudland, Philip S ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NONE

Author keywords

Cell adhesion; Cell motility; Metastasis; Osteopontin; Tumorigenesis

Indexed keywords

CALCIUM BINDING PROTEIN; OSTEOPONTIN; PHOSPHOPROTEIN;

AMINO ACID SEQUENCE; BINDING AFFINITY; CARCINOGENESIS; CELL ADHESION; GENETIC CONSERVATION; HUMAN; METASTASIS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL ADHESION; CELL MOVEMENT; DISEASE MODELS, ANIMAL; HUMANS; MACROPHAGES; NEOPLASM METASTASIS; NEOPLASMS; OSTEOPONTIN; RECEPTORS, VITRONECTIN; SIALOGLYCOPROTEINS; SIGNAL TRANSDUCTION;

EID: 0030782774     PISSN: 02511789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Denhardt DT, Guo X: Osteopontin: A protein with diverse functions. FASEB J 1993;7:1475-1482.
2. Butler, WT: Structural and functional domains of osteopontin. Osteopontin. Ann NY Acad Sci 1995; 760:6-11.
3. Brown LF, Berse B, Van De Water L, Papadopoulos-Sergiou A, Peruzzi CA, Manseau EJ, Dvorak HF, Senger DR: Expression and distribution of osteopontin in human tissues: Widespread association with luminal epithelial surfaces. Mol Biol Cell 1992;3:1169-1180.
4. Chackalaparampil I, Banerjee D, Poirier Y, Mukherjee BB: Altered processing of a major secreted phosphoprotein correlates with tumorigenicity in Rous sarcoma virus-transformed mammalian cells. J Virol 1985;53:841-850.
5. Oldberg A, Franzen A, Heinegard D: Cloning and sequence of analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 1986;83:8819-8823.
6. Prince CW, Oosawa T, Butler WT, Tomana M, Bhown AS, Bhown M, Schrohenloher RE: Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem 1987;262: 2900-2907.
7. Smith JH, Denhardt DT: Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cells: Induction is stable at high, but not at low, cell densities. J Cell Biochem 1987;34:13-22.
8. Patarca R, Freeman GJ, Singh RP, Wei F-Y, Durfee T, Blattner F, Regnier DC, Kozak CA, Mock BA, Morse HC III, Jerrells TR, Cantor H: Structural and functional studies of the early T lymphocyte activation (Eta-1) gene. J Exp Med 1989;170: 145-161.
9. Senger DR, Perruzzi CA, Papadopoulos A: Elevated expression of secreted phosphoprotein 1 (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 1989;9:1291-1300.
10. Giachelli CM, Bae N, Lombardi DM, Majesky MW, Schwartz SM: Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2ar). Biochem Biophys Res Commun 1991;177:867-873.
11. Craig AM, Smith JH, Denhardt DT: Osteopontin, a transformation-associated cell adhesion phosphoprotein, is induced by a 12-O-tetradecanylphorbol 13-acetate in mouse epidermis. J Biol Chem 1989;264: 9682-9689.
12. Manuel MP, Prince CW, Oosawa T, Gay S, Bronckers ALJJ, Butler WT: Immunohistochemical demonstration of a 44-Kd phosphoprotein in developing rat bones. J Histochem Cytochem 1987;33:707-715.
13. Reinholt FP, Hultenby K, Oldberg A, Heinegard D: Osteopontin - a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA 1990; 87:4477-4475.
14. 3 stimulates synthesis and secretion of nonphosphorylated osteopontin (secreted phosphoprotein 1) in mouse JB6 epidermal cells. Cancer Res 1991;51: 2144-2150.
15. 3 integrin is present on human osteoclasts. Exp Cell Res 1993;205:345-352.
16. 3 receptor potentiate bone resorption. J Biol Chem 1993;268: 9901-9907.
17. Soriano P, Montgomery C, Geske R, Bradley A: Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64: 693-702.
18. Chackalaparampil I, Peri A, Nemir M, McKee MD, Lin P, Mukherjee BB, Mukherjee AB: Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extra-cellular matrix protein. Oncogene 1996;12:1457-1467.
19. Groves MG, Osterman JV: Host defences in experimental scrub typhus: Genetics of natural resistance to infection. Infect Immun 1978;19:583.
20. Giachelli CM, Liaw L, Murry CE, Schwartz SM, Almeida M: Osteopontin expression in cardiovascular diseases. Osteopontin. Ann NY Acad Sci 1995;760:109-126.
21. Yamada KM: Adhesive recognition sequences. J Biol Chem 1991;266: 12809-12812.
22. Chambers AF, Hota C, Prince CW: Adhesion of metastatic, ras-transformed NIH 3T3 cells to osteopontin, fibronectin, and laminin. Cancer Res 1993;53:701-706.
23. Bautişta DS, Xuan J-W, Hota C, Chambers AF, Harris JF: Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 1994;269: 23280-23285.
24. Xuan J-W, Hota C, Chambers AF: Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem 1994;54:247-255.
25. D'Errico JA, Sauk JJ, Prince CW, Somerman MJ: Osteopontin adhesion receptors on gingival fibroblasts. J Peridont Res 1995;30:34-41.
26. Singh RP, Patarca R, Schwartz J, Singh P, Kantor H: Definition of a specific interaction between early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effects upon macrophages in vivo. J Exp Med 1990;171:1931-1942.
27. Xuan J-W, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, Chambers AF: Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migratory functions. J Cell Biochem 1995;57:680-690.
28. Senger DR, Perruzzi CA: Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta 1996;1314:13-24.
29. Liaw L, Almeida M, Downey W, Hart CE, Schwartz SM, Giachelli CM: Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994;74:214-224.
30. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM: The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. J Clin Invest 1995;95:713-724.
31. 1 integrin. J Biol Chem 1996;271:28485-28491.
32. Senger DR, Brown LF, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L: Osteopontin at the tumor/ host interface; in Denhardt DT, Butler WT, Chambers AF, Senger DR (eds): Osteopontin. Ann NY Acad Sci 1995, vol 760, pp 83-100.
33. Hynes RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
34. Gianocotti FG, Mainiero F: Integrin-mediated adhesion and signaling in tumorigenesis. Biochim Biophys Acta 1994;1198:47-64.
35. 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 1991;266: 20369-20374.
36. 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments. J Biol Chem 1992;67:5070-5077.
37. 5. J Biol Chem 1995;270:26232-26238.
38. van Dijk S, D'Errico JA, Somerman MJ, Farach-Carson MC, Butler WT: Evidence that a non-RGD domain in rat osteopontin is involved in cell attachment. J Bone Miner Res 1993; 8:1499-1506.
39. v integrins. J Cell Biochem 1996;62:123-131.
40. Weber GF, Ashkar S, Glimcher MJ, Cantor H: Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-512.
41. Teti A, Blair HC, Schlesinger P, Grano M, Zambonin-Zallone A, Kahn AJ, Teitelbaum SL, Hruska KA: Extracellular protons acidify osteoclasts, reduce cytosolic calcium, and promote expression of cell-matrix attachment structures. J Clin Invest 1989;84:773-780.
42. 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity; in Denhardt DT, Butler WT, Chambers AF, Senger DR (eds): Osteopontin. Ann NY Acad Sci 1995, vol 760, pp 151-165.
43. 3 by osteopontin stimulates phosphoinositol 3-hydroxyl kinase activity. Endocrinology 1996;136:2984-2992.
44. Denhardt DT, Lopez CA, Rollo EE, Hwang S-M, An XR, Walther SE: Osteopontin-induced modifications of cellular functions; in Denhardt DT, Butler WT, Chambers AF, Senger DR (eds): Osteopontin. Ann NY Acad Sci 1995, vol 760, pp 127-142.
45. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui P-Y: Control of adhesiondependent cell survival by focal adhesion kinase. J Cell Biol 1996;134: 793-799.
46. Craig SW, Johson RP: Assembly of focal adhesions: Progress, paradigms, and portents. Curr Opin Cell Biol 1996;8:74-85.
47. Parsons JT, Schaller MD, Hildebrand J, Leu T-H, Richardson A, Otey C: Focal adhesion kinase: Structure and signalling. J Cell Sci 1994;18:109-113.
48. v-subunit. Endocrinology 1996;137: 2432-2440.
49. Senger DR, Perruzzi CA, Gracey CF, Papadopoulos A, Tenen DG: Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation. Cancer Res 1988;48:5770-5774.
50. Chambers AF, Tuck AB: Ras-responsive genes and tumor metastasis. Crit Rev Oncog 1993;4:95-114.
51. Brown LF, Papadopoulos-Sergiou A, Brygida B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR: Osteopontin expression in human carcinomas. Am J Pathol 1994; 145:610-623.
52. O'Sullivan C, Lewis CE: Tumour-associated leucocytes: Friends or foe in breast carcinoma. J Pathol 1994; 172:229-235.
53. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56:4625-4629.
54. Hirota S, Ito A, Nagoshi J, Takeda M, Kurat A, Takatsuka Y, Kohri K, Nomura S, Kitamura Y: Expression of bone matrix messenger ribonucleic acids in human breast cancers. Lab Invest 1995;72:64-69.
55. Bellahcene A, Castronovo V: Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995;146:95-100.
56. Saitoh Y, Kuratsu JI, Takeshima H, Yamamoto S, Ushio Y: Expression of osteopontin in human glioma. Lab Invest 1995;72:55-63.
57. Chambers AF, Denhardt GH, Wilson S: ras-transformed NIH 3T3 cell lines, selected for metastatic ability in chick embryos, have increased proportions of p21-expressing cells and are metastatic in nude mice. Invasion Metastasis 1990;10:225-240.
58. Su ZZ, Austin VN, Zimmer SG, Fisher PB: Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Oncogene 1993;8:1211-1219.
59. Dunnington D, Hughes CM, Monaghan P, Rudland PS: Phenotypic instability of rat mammary epithelial tumor cells. J Natl Cancer Inst 1983;71:1227-1240.
60. Jamieson S, Barraclough R, Rudland PS: Transfection of a non-metastatic diploid rat mammary epithelial cell line with oncogenes for EJ-ras-1 and polyoma large T antigen. Int J Cancer 1990;46:1071-1080.
61. Chen H, Ke Y, Oates AJ, Barraclough R, Rudland PS: Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene, in press.
62. Rudland PS, Hallowes RC, Cox SA, Ormerod EJ, Warburton MJ: Loss of production of myoepithelial cells and basement membrane proteins but retention of response to certain growth factors and hormones by a new malignant human breast cancer cell strain. Cancer Res 1985;45: 3864-3877.
63. Davies BR, Barraclough R, Rudland PS: Induction of metastatic ability in a stably diploid benign rat mammary epithelial by transfection with DNA from human malignant breast carcinoma cell lines. Cancer Res 1994;54:2785-2793.
64. Oates AJ, Barraclough R, Rudland PS: The identification of osteopontin as a metastasis-associated gene product in a rodent mammary tumour model. Oncogene 1996;13: 97-104.
65. Davies BR, Davies MPA, Gibbs FEM, Barraclough R, Rudland PS: Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. Oncogene 1993;8: 999-1008.
66. Barraclough R, Rudland PS: The S-100-related calcium-binding protein, p9Ka, and metastasis in rodent and human mammary cells. Eur J Cancer 1994;30A:1570-1576.
67. Hart IR, Saini A: Biology of tumour metastasis. Lancet 1992;339:1453-1457.
68. Guo X, Zhang YP, Mitchell DA, Denhardt DT, Chambers AF: Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative Ets-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol Cell Biol 1995;15:476-487.
69. Tezuka K-I, Denhardt DT, Rodan GA, Harada S-I: Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor. J Biol Chem 1996; 271:22713-22717.
70. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF: Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 1994;54:832-837.
71. Gardner HAR, Berse B, Senger DR: Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat 1 fibroblasts. Oncogene 1994;9: 2321-2326.
72. Feng B, Rollo EE, Denhardt DT: Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: Evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clin Exp Metastasis 1995;13:453-462.
73. Stetler-Stevenson WG, Liotta LA, Kleiner DE: Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993:7:1434-1441.
74. 3 subunit with tumor progression. Cancer Res 1990;50: 6757-6764.
75. 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992;89:1557-1561.
76. 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 1991;88:1924-1932.
77. Humphries MJ, Olden K, Yamada KM: A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986;233:467-470.
78. Gibbs FE, Wilkinson MC, Rudland PS, Barraclough R: Interactions in vitro of P9Ka, the rat S-100-related, metastasis-inducing, calcium-binding protein. J Biol Chem 1994;269: 18992-18999.
79. Lauffenburger DA, Horwitz AF: Cell migration: A physically integrated process. Cell 1996;84:359-369.
80. Archer S: Measurement of nitric oxide in biological models. FASEB J 1993;7:349-360.
81. Hwang SM, Lopez CA, Heck DE, Gardner CR, Laskin DL, Laskin JD, Denhardt DT: Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in murine kidney epithelial cells. J Biol Chem 1994;1:711-715.
82. Singh K, Balligand JL, Fischer TA, Smith TW, Kelly RA: Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. J Biol Chem 1995;270:28471-28478.
83. Denhardt DT, Chambers AF: Overcoming obstacles to metastasis - defence against host defences: Osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 1994;56:48-51.